Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Health minister named as Haiti's new interim prime minister
21 Dec 2014 at 8:17am
By Amelie Baron PORT-AU-PRINCE (Reuters) - Haitian Health Minister Florence Duperval Guillaume was named interim prime minister on Sunday to replace Laurent Lamothe, who resigned a week ago following several weeks of protests. The announcement is part of an effort to resolve a mounting political crisis over long-delayed elections. Lamothe's resignation also came after international warnings from the United States and the United Nations that the impoverished Caribbean nation was on the brink of political chaos again. ...
Ebola response in rural Sierra Leone not yet rapid enough
21 Dec 2014 at 7:13am
By Emma Farge KOIDU, Sierra Leone (Reuters) - The rapid response team has arrived and the chaos is easing, but medics in a remote Sierra Leonean district are struggling to control a local Ebola outbreak when it's too late to nip it in the bud. A deployment of medical workers and equipment to Kono District has been the fastest so far in Sierra Leone, a country with nearly half the total Ebola cases,- under a strategy of tackling epidemic hotspots before they get too big. ...
BUSTED: 4 Common Myths About Catching Cold In Cold Weather
21 Dec 2014 at 6:17am
Does exposure to cold weather really make you more likely to catch a cold? No, it doesn't. In fact, as a new YouTube video entitled Cold Weather Myths explains, research suggests just the opposite: frigid temps lower the risk of catching cold by stimulating the body's production of infection-fighting immune cells known as granulocytes.And you...
As Ford closes, European rust belt seeks new ideas
21 Dec 2014 at 4:16am
By Robin Emmott and Robert-Jan Bartunek GENK, Belgium (Reuters) - In the heart of western Europe, the Belgian-Dutch-German rust belt has been dealt another blow. Two car plants closed this month as companies sought cheaper labor elsewhere, the final chapter of a manufacturing boom that began when coal mines fuelling Europe's industrialization shut in the 1960s. The final production day at Ford Motor Co?s plant in the eastern Belgian city of Genk came barely two weeks after General Motors closed its Opel Bochum factory across the border in Germany, both part of automakers' strategy to adapt to falling sales following the euro zone crisis. "I worked at Ford Genk for almost 40 years, I've never applied for another job in all my life," said Pierre Boonen, 57, after one of his last shifts at the plant that generated work directly or indirectly for around 10,000 people.
Britain lifts bird flu restrictions on duck farm
21 Dec 2014 at 1:45am
LONDON (Reuters) - Britain on Sunday lifted restrictions on the movement of poultry in a six-mile (9.7-km) zone around a duck farm in northern England where the highly contagious H5N8 bird flu strain was found last month. The Department for Environment, Food and Rural Affairs (Defra) said in a statement that all restrictions, including those covering the storage, transport and sourcing of meat products, had been lifted. ...
U.N.'s Ebola mission should be closed once battle won: Ban
20 Dec 2014 at 11:53pm
By Matthew Mpoke Bigg BAMAKO (Reuters) - The United Nations mission to fight Ebola should be wound down quickly once the battle is won, U.N. Secretary General Ban Ki-moon said on Saturday during his first tour of countries stricken with the virus. The U.N. emergency Ebola response mission, or UNMEER, was set up in September to coordinate policy and logistics for a campaign that includes governments, charities and healthcare workers from affected countries. Ban said UNMEER differed from peacekeeping missions and should not outlive its immediate purpose. ...
Liberian voter turnout low as Ebola overshadows senate election
20 Dec 2014 at 11:27pm
By James Harding Giahyue MONROVIA (Reuters) - Turnout for Liberian parliamentary elections on Saturday appeared to be low as concerns about Ebola kept many voters at home. Polling stations were largely empty after voting began at 8 a.m. (0800 GMT) in the seafront capital Monrovia, with voters occasionally drifting in, despite precautions put in place by the National Elections Commission (NEC). Staff with temperature guns at polling stations checked voters for any signs of the hemorrhagic fever, which is spread via bodily fluids. ...
South Korea halts U.S. poultry imports due to bird flu in U.S.
20 Dec 2014 at 7:42pm
By Meeyoung Cho SEOUL (Reuters) - South Korea has suspended imports of U.S. poultry and poultry products because of an outbreak of bird flu in the United States, the Agriculture Ministry said in a statement on Sunday. The suspension, from Saturday, comes as South Korea is struggling to contain its own outbreak of bird flu in birds. "This import suspension is a quarantine measure to prevent the HPAI virus from entering the country," the ministry statement said, referring to highly pathogenic avian influenza (HPAI) virus. ...
Child tests negative for Ebola at Chicago hospital
20 Dec 2014 at 12:33pm
(Reuters) - A child being monitored for Ebola in a Chicago hospital has been discharged after testing negative for the virus, the state health agency said on Saturday. Federal officials screening for Ebola at O'Hare International Airport in Chicago detected a fever in the child, who had been held in isolation at the University of Chicago Medical Center for monitoring since Friday. "Tests by the Illinois Department of Public Health confirmed a negative result for Ebola," the Illinois Department of Public Health said in a statement. ...
Liberia holds Senate vote amid Ebola fears
20 Dec 2014 at 11:04am
MONROVIA, Liberia (AP) ? Health workers carrying thermometers and sanitizers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.
Sierra Leone peacekeepers to leave Somalia mission
20 Dec 2014 at 8:34am
FREETOWN, Sierra Leone (AP) ? A Sierra Leone military official says the country is withdrawing from the African Union peacekeeping force in Somalia after being blocked from rotating its soldiers over concerns about the spread of Ebola.
WHO: Recorded Ebola deaths top 7,000
20 Dec 2014 at 7:20am
CONAKRY, Guinea (AP) ? The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban Ki-moon continued his tour of Ebola-affected countries in West Africa on Saturday.
Child being observed at Chicago hospital to rule out Ebola
20 Dec 2014 at 6:52am
By Mary Wisniewski CHICAGO (Reuters) - A child who arrived in Chicago with a fever was under observation on Friday at a city hospital to rule out the Ebola virus, hospital officials said. Federal officials screening arriving passengers at O'Hare International Airport detected the fever, but no other symptoms of the disease, the University of Chicago Medical Center said in a statement. The patient was isolated under strict quarantine protocols until the child?s condition improves and a diagnosis is established, the hospital said. The child was in stable condition. ...
Ebola death toll in three African countries hits 7,373: WHO
20 Dec 2014 at 5:57am
GENEVA (Reuters) - The death toll from Ebola in the three worst-affected countries in West Africa has risen to 7,373 among 19,031 cases known to date there, the World Health Organization said on Saturday. The latest data, posted overnight on the WHO website, reflected nearly 500 new deaths from the worst ever outbreak of the hemorrhagic fever in Guinea, Liberia and Sierra Leone since previous WHO figures were issued on Dec. 17. Sierra Leone accounts for the most cases, 8,759, against 7,819 for Liberia. ...
UN's Ban urges end to discrimination against Ebola workers
20 Dec 2014 at 5:55am
By Matthew Mpoke Bigg CONAKRY (Reuters) - U.N. Secretary-General Ban Ki-moon on Saturday urged countries affected by the Ebola virus to avoid discriminating against healthcare workers fighting to end the disease. Ban was speaking in Guinea on the second day of a whistle-stop tour aimed at thanking healthcare workers of the countries at the heart of the epidemic. According to the latest World Health Organization figures, 7,373 people have died of Ebola in the three worst-affected countries, Liberia, Sierra Leone and Guinea. ...